GENE ONLINE|News &
Opinion
Blog

2025-12-01|

Study Explores Genetic Markers and Polygenic Risk in Kidney Function Using Whole Exome Sequencing

by GOAI
Share To

A recent study examined the connection between kidney function and genetic factors using whole exome sequencing and polygenic risk assessment. Researchers, led by Lin et al., analyzed genetic data from diverse populations to investigate how variations in genetic makeup influence kidney health. The study focused on identifying specific genetic markers and assessing cumulative genetic risks that may contribute to kidney-related conditions.

The research utilized advanced techniques in exome sequencing, which examines protein-coding regions of the genome, alongside polygenic risk scoring, a method that evaluates the combined impact of multiple genetic variants. By integrating these approaches, the team aimed to uncover insights into how genetics affect kidney function across different demographic groups. Findings from this investigation provide detailed information about potential genetic contributors to kidney health disparities and offer a foundation for further exploration into personalized medical strategies for managing kidney diseases.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top